Rhodiola Rosea: Stress, Fatigue, Mood and Safety Evidence

Table of contents

• Evidence summary
• What Rhodiola is
• Forms and preparations
• Proposed mechanisms
• The hype vs the evidence
• Benefits by claim
• Claims and limits
• Safety reports and gaps
• Medicines and evidence gaps
• Who should seek advice first
• Studied and traditional-use protocols
• How preclinical evidence is used
• Funding, conflicts and source roles
• Frequently asked questions
• Sources and funding notes

What Rhodiola is

Rhodiola rosea, also called golden root or arctic root, grows in cold and high-altitude regions; preparations use its roots and rhizomes (NCCIH; EMA description). “Adaptogen” describes a proposed broad response to stress, not an established treatment indication. Marker content and extraction differ between preparations; the 2012 review describes an approximate natural 3:1 ratio, not a universal batch specification or proof that a similar label reproduces a trial (constituents and trial table).

Forms and preparations

The studied preparation, extraction method, quantity and marker content matter more than a capsule, powder or liquid label alone. The examples below do not rank efficacy or safety.

Proposed mechanisms

Proposed explanations include HPA-axis and monoamine effects, with much of the evidence coming from animals or laboratory systems (narrative mechanism discussion; EMA nonclinical assessment). Some human protocols measured symptoms or cortisol, but a biomarker change does not establish the whole proposed pathway or a reliable treatment effect (clinical trial summaries). “Adaptogen” is a hypothesis-oriented label, not proof that rhodiola normalises every person’s stress response.

The hype vs the evidence

Stress, burnout and focus claims need evidence about meaningful clinical outcomes, not only an adaptogen label or a positive symptom change in an uncontrolled study. The studies discussed here differ in preparations, comparators and populations.

The Ishaque review assessed 11 trial units using searches through July 2009. It reported two of six physical and three of five mental-fatigue trials as positive; inconsistent endpoints prevented meta-analysis. All studies had high or unclear risk of bias/reporting limitations, and some physical protocols combined ingredients. These counts describe that review, not the probability that a person benefits. The 2024 EMA assessment also found insufficient clinical evidence for well-established use; NCCIH considers current health-purpose evidence insufficient.

The Mao 2015 original report randomized 57 people to rhodiola, sertraline or placebo for 12 weeks. Between-group differences on the depression scales were not significant. Adverse events were reported by 30.0%, 63.2% and 16.7%, respectively; the overall three-group comparison was significant (p=0.012), not a proof of every pairwise difference. NIH/NCCAM and the Jack Warsaw Fund supported the work; the Swedish Herbal Institute supplied SHR-5 and was reported to have no design/conduct/report role. Numerically different symptom changes do not prove superiority, inferiority or equivalence.

The 2022 review presents favourable stress and performance narratives and has two Natac Biotech-affiliated authors. It also declares HEALTH4BRAIN public project support and no conflicts. Those declarations do not eliminate commercial ties or establish the validity of each cited result. Its positive interpretation of Mao’s trial should be read beside the original nonsignificant between-group comparisons (original trial); selected numerical changes do not establish efficacy or equivalence.

Benefits by claim

Physical fatigue

The 2012 review reported positive physical-fatigue findings in two of six trial units, with high or unclear bias/reporting problems and differing preparations; two physical protocols included Cordyceps and a proprietary blend (original Results). Review support came from CFI, AVAC, ACIDF and AARD, with Vohra salary support from Alberta Innovates–Health Solutions; no personal/financial competing interests were declared. Those disclosures do not clear every underlying trial’s funding. The mixed historical findings do not establish a reliable general effect.

Mental fatigue and “focus under pressure”

The review reported three of five mental-fatigue trials as positive, but unclear/high bias, nonvalidated measures and incomplete analyses limited confidence (original mental-fatigue Results). One protocol involved night-duty physicians and another students under examination stress; this does not establish reliable focus enhancement across everyday users.

Stress and burnout

EMA discusses a small controlled stress-related fatigue trial and several open stress/burnout studies. Its assessment did not accept well-established clinical efficacy (clinical assessment). The 2012 review flags excluded data and other limitations in the controlled fatigue trial (Olsson analysis). A burnout score or improvement without a control group is not proof of treating every form of occupational burnout.

Mood and depression

The small rhodiola/sertraline/placebo trial did not establish a depression benefit over placebo or equivalence to sertraline. Its numerical pattern and tolerability findings are preliminary, with commercial extract supply disclosed.

The “adaptogen”/HPA-axis narrative

The reviewed evidence does not establish a universal HPA-axis treatment mechanism. Preclinical findings and human symptom/cortisol observations have different roles (EMA assessment; reviewed clinical endpoints). Mao’s response-based dose escalation also prevented a clean dose-response inference; its authors state that limitation (original Discussion).

Claims and limits

Safety reports and gaps

Mao reported no treatment-related serious adverse events, but six of 20 rhodiola participants (30.0%) reported study-related events; that small selected trial is not a universal safety rate (original Results/Table 2). A 2022 case described hospital presentation with mania after a man reported taking three times the recommended rhodiola amount alongside other supplements. Product/dose details and causality remain uncertain (original case). EMA discusses mostly non-serious trial events and suspected postmarketing reports with unknown frequency (safety assessment).

Medicines and evidence gaps

Who should seek advice first

• People taking psychiatric medicines: the paroxetine case and EMA’s suspected reports warrant prescriber review, with causality and frequency uncertain (case abstract; assessment). Do not alter prescribed treatment based on a supplement comparison.
• People with bipolar vulnerability or troublesome insomnia, agitation or dizziness: short selected studies do not establish safety for these situations. EMA lists nervous-system effects, and the high-dose mania case is a confounded signal (safety assessment; original case). Evening-specific risk has not been established here.
• Pregnant or breastfeeding people, children and adolescents: EMA does not recommend use because relevant safety has not been established. Hypersensitivity to the active substance is its monograph contraindication (special populations and contraindication). These are preparation-specific regulatory precautions, not a quantified universal harm rate.
• Anyone considering replacement of depression treatment: the small three-arm trial did not establish rhodiola benefit over placebo or equivalence; it excluded actively suicidal patients and several other vulnerable groups (original Methods/Results). Seek clinical care for depression and discuss treatment changes with the prescriber (NCCIH guidance).
• People assessing review conclusions: consider author affiliations, declared support and methods separately. The Natac-affiliated review has public project support and a no-conflict declaration; the Ishaque review has development-related grants and author salary support. Neither institutional label clears all underlying-study finance (2022 review; 2012 disclosures).

Studied and traditional-use protocols

How preclinical evidence is used

Human clinical outcomes, regulatory assessments and individual case reports answer different questions. A trial can assess a selected protocol, while a case report can flag a possible harm without determining frequency. Funding, author ties and study design are evaluated separately.

• Animal or laboratory findings may suggest pathways; they do not establish human fatigue, mood or burnout treatment. EMA separates nonclinical studies from its clinical assessment (original report). Ishaque’s trial appraisal addresses clinical outcomes and reporting quality, not confirmation of every proposed HPA mechanism (review Methods/Results).

The conclusions here concern the outcomes and preparations actually discussed. They are not an exhaustive census of all human studies, every medication interaction or every underlying funder. Unreported or inaccessible financial details remain unknown.

Funding, conflicts and source roles

Frequently asked questions

Does rhodiola actually work for stress and fatigue?

The reviewed findings are mixed and do not establish reliable universal stress/fatigue relief. Ishaque’s historical review reported two of six physical and three of five mental-fatigue trials as positive, with high or unclear bias and no pooled effect (original review). EMA did not accept well-established clinical efficacy, and NCCIH considers the evidence insufficient (2024 assessment; guidance). That does not prove every preparation ineffective.

Is rhodiola as good as an antidepressant for mood?

The cited trial does not establish that claim. Depression-scale comparisons among rhodiola, sertraline and placebo were not significant; a null comparison is not proof of equivalence (Mao 2015).

What is the SHR-5 extract mentioned in rhodiola research?

SHR-5 is a specified extract used in several protocols, not a universal retail grade. Mao’s capsules contained 3.07% rosavin and 1.95% rhodioloside (Methods); other reviewed marker contents differ (trial table). A similar ratio or name alone does not establish another product’s clinical equivalence.

Why are some rhodiola reviews more positive than others?

Reviews differ in searches, study selection and appraisal, as well as author and funding context. The 2022 narrative review has Natac Biotech affiliations and HEALTH4BRAIN support, with no conflicts declared (original). Ishaque’s historical systematic review has declared development grants and salary support and found high/unclear bias (original). Read those disclosures beside actual methods and original outcomes; commercial ties alone neither disprove a result nor certify a cautious review as independent.

Can rhodiola be combined safely with antidepressants or other medications?

Do not assume safety of every combination. The paroxetine case is a possible signal (abstract); the human probe study found a changed CYP2C9-related losartan ratio but did not test warfarin/phenytoin clinical harm (original). EMA considers clinical relevance unclear and also discusses suspected reports (assessment). Ask the prescriber or pharmacist about the exact product and medicines (guidance).

Is rhodiola an approved medicine?

EMA’s monograph concerns a defined dry extract and long-standing use for stress symptoms; it did not accept well-established clinical efficacy. National product registration is distinct from a blanket EMA approval of every rhodiola product (original assessment). In the US, dietary supplements follow a different framework from approved medicines and are not FDA-approved before sale (official guidance).

Sources and funding notes

• Ishaque 2012 original — historical qualitative fatigue review, high/unclear bias, mixed preparations; development grants and Vohra salary support disclosed.
• Mao 2015 original — 57-person depression trial, null between-group scales and reported adverse events; NIH/fund support and commercial extract supply, with role/declarations qualified.
• 2022 narrative review — Natac-affiliated authors, HEALTH4BRAIN project support and no-conflict declaration; positive narrative is not independent original-outcome verification.
• Maniscalco case abstract — possible paroxetine-associated symptoms; full original funding/COI inaccessible. Whig/Leo 2022 original case — high-dose, multiple-supplement mania signal; no support/conflicts declared, causality unestablished.
• EMA 2024 revision 1 — preparation-specific traditional-use, clinical and safety assessment. Thu 2016 original — CYP probe study, surrogate ratio and unresolved clinical relevance. NCCIH guidance — current official evidence/safety/regulatory information.